1. In Vivo

Sanofi's Acomplia Stumbles

It seems FDA isn't as comfortable as some thought about letting Sanofi-Aventis' much-vaunted obesity candidate rimonabant (Acomplia) onto the market. But the agency's caution--and that's all it appears to be--isn't so surprising.

It seems FDA isn't as comfortable as some thought about letting Sanofi-Aventis ' much-vaunted obesity candidate rimonabant (Acomplia) onto the market. The agency in February issued an approvable letter for the first-in-class cannabinoid-1 receptor antagonist in weight management—meaning further information is required--and a not approvable in smoking cessation, which is basically a "No."

The news hit the headlines, nudging Sanofi-Aventis' share price down by a few percentage points. Acomplia is one of the...

More from Archive

More from In Vivo

Rising Leaders 2025: Doxie Jordan, From UNC Graduate To Global Market Strategist

 
• By Jo Shorthouse

Bristol Myers Squibb executive Doxie Jordan discusses his path to global commercial leadership and the principles guiding pharmaceutical market strategy

Podcast: Brain+ CEO Discusses “Groundbreaking” Potential Of CST Assistant For Dementia Patients

 
• By Anabel Costa-Ferreira

Devika Wood, CEO of Brain+, explains the importance of developing health tech solutions for dementia and the growing need to both raise awareness and improve overall access to nondrug interventions like CST.

Behind The Buyout: Dispatches From The Dealmaking Table

 
• By Jo Shorthouse

In a challenging funding environment for biopharma, strategic dealmaking has become a critical growth engine. In Vivo explores what it truly takes to navigate high-stakes acquisitions and partnerships, drawing on insights from seasoned industry leaders.